Journey Medical Corp (DERM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Journey Medical Corp (DERM) has a cash flow conversion efficiency ratio of -0.200x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.36 Million) by net assets ($31.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see DERM market cap overview for the company's overall valuation and market capitalisation.
Journey Medical Corp - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Journey Medical Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Journey Medical Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Journey Medical Corp ranked by their cash flow conversion efficiency. Explore Journey Medical Corp cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Muhak Co. Ltd
KO:033920
|
-0.009x |
|
AirBoss of America Corp.
TO:BOS
|
0.015x |
|
Daios Plastics S.A.
AT:DAIOS
|
N/A |
|
Bank Capital Indonesia Tbk
JK:BACA
|
0.445x |
|
NH SPAC 2
KQ:206640
|
0.043x |
|
Diamond Building Products Public Company Limited
BK:DRT
|
0.054x |
|
Atrem S.A.
WAR:ATR
|
-0.108x |
|
Tenaya Therapeutics Inc
NASDAQ:TNYA
|
-0.188x |
Annual Cash Flow Conversion Efficiency for Journey Medical Corp (2014–2025)
The table below shows the annual cash flow conversion efficiency of Journey Medical Corp from 2014 to 2025. View Journey Medical Corp stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $31.85 Million | $-12.44 Million | -0.391x | +14.12% |
| 2024-12-31 | $20.07 Million | $-9.13 Million | -0.455x | -276.62% |
| 2023-12-31 | $20.35 Million | $5.24 Million | 0.257x | +132.31% |
| 2022-12-31 | $16.98 Million | $-13.53 Million | -0.797x | -1436.30% |
| 2021-12-31 | $42.04 Million | $-2.18 Million | -0.052x | -110.40% |
| 2020-12-31 | $10.29 Million | $5.13 Million | 0.499x | -84.78% |
| 2019-12-31 | $2.75 Million | $9.02 Million | 3.277x | -86.10% |
| 2018-12-31 | $-9.04 Million | $-213.10 Million | 23.575x | +3493.55% |
| 2017-12-31 | $149.65 Million | $-103.96 Million | -0.695x | -131.88% |
| 2016-12-31 | $247.37 Million | $-74.11 Million | -0.300x | -14.71% |
| 2015-12-31 | $185.47 Million | $-48.44 Million | -0.261x | -27.73% |
| 2014-12-31 | $153.58 Million | $-31.40 Million | -0.204x | -- |
About Journey Medical Corp
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat sev… Read more